Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 - Wikidata - wikimedia - TriplyDB

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

http://www.wikidata.org/entity/Q33398722

about

Muscle-invasive urothelial bladder cancer: an update on systemic therapy Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery How to optimally manage elderly bladder cancer patients?Bladder cancer in the elderly patient: challenges and solutions Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Systemic therapy for bladder cancer finally comes into a new age.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder.Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.Systemic therapy in bladder cancer Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.Chemotherapy in advanced bladder cancer: current status and future Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.Urothelial carcinoma management in elderly or unfit patients.Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Circulating Biomarkers in Bladder Cancer.Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.New discoveries in the molecular landscape of bladder cancer.NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.Novel molecular targets for the therapy of urothelial carcinoma.Sunitinib malate in the treatment of urothelial cancer.Emerging drugs for urothelial carcinoma.Update in systemic therapy of urologic malignancies.New treatments for bladder cancer: when will we make progress?Optimal treatment for metastatic bladder cancer.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Targeting the VEGF pathway in metastatic bladder cancer.The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.Docetaxel for the treatment of bladder cancer.Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines Emerging drugs for urothelial (bladder) cancer.

P2860

Q26775780-6BFF53DC-2048-485C-9EF8-6DA40429D696 Q28074930-B1BFBA8B-1EF1-4EC0-B8E4-42DB2A8B42F1 Q28076939-AEBD342E-9DD9-4173-BE06-82EA3A0C02DF Q28082782-FF9A122C-082E-43E4-B33C-0244DF14EE73 Q30240816-5C57D45A-9A10-4B85-B03B-B43C630CA5E6 Q30249047-E743176F-9E6F-450F-915F-D8E5067086B5 Q30275266-5C47DBE1-7A23-4FDA-8B05-8A693DBA84DE Q30277192-2F5B2E28-77EF-4195-988C-31DADE92ED3F Q30489412-9AE44B5C-1206-4961-AD47-1EE3ABB008C2 Q33407440-A57EE07E-E731-408E-9B62-1DF72CB54D35 Q33411962-F9AEDDA2-B107-4564-9AE9-845A6B6D1A70 Q33578564-3D25A291-4970-43A2-8DD0-1003620CB635 Q35180823-D7F60B46-B297-4C4C-B3F1-B3B4E7A32FA8 Q35227771-206C3F0F-316E-4A5B-B426-EBF71E7BA080 Q36103157-FE0A8638-590B-4366-A5E5-772EBCA1CA28 Q36615090-BBAEB82E-769A-4D39-945D-557ADB20F8F6 Q36627206-214BE8C3-0B4F-478A-B6F5-CA5D971FCC0A Q36953563-90D2A70D-82B5-4251-9E34-CB14D7EAAC2D Q37030514-AB9ADB7B-F4B2-410E-B80C-5EBA4AE24744 Q37045540-9CF78E2C-6276-491B-AAF8-6545CD388891 Q37108266-FCB02BFE-F8E6-48F7-BB62-298597887965 Q37187791-014EFCE8-23DC-4EE6-9BFA-40CC7A236B44 Q37323009-339E7A93-27A2-460A-AC31-723A0A224095 Q37475193-997874C4-E7EA-414E-981F-768EC79B61BA Q37530401-7759AA79-8863-4AD5-B793-4D9ABB037A57 Q37555069-C84762A2-4AB3-496B-B4E1-4A4F6DD1A33A Q37578747-54E4D785-EE29-4A71-8A38-36321EF87923 Q37736774-ED4AB50B-AF43-4CB4-877A-4001810452EE Q38003195-292BD6F9-7DD2-434A-B950-150083523699 Q38159713-4BC014BF-DEB3-4893-8B2F-82130F664B7C Q38160271-46DC964B-ED7A-4550-8AD2-C86BFAC34670 Q38176143-472139BF-9C04-4DEA-9D6A-81628F3FEA13 Q38177753-CBB0E01D-B9C6-4ED5-99C2-472322A8E0C4 Q38233326-EB73BF80-9250-4061-8D55-B7A7969418D7 Q38312045-5BFE35DB-6048-4347-AE57-3A2616DFB12C Q38534167-4D6EAAF0-400C-4203-9C92-B21D8BEB28F9 Q38612965-0A017602-8C68-4813-9C30-33D6DCCFCBBB Q38624895-7C3350C8-0E57-483D-AF9E-1688AB2C3FFA Q38647100-717A3ADA-0130-4D5E-A65D-23C8A257B11C Q38677414-DFB3E4C1-88AB-411E-94C1-6AE294D25194

P2860

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

http://www.wikidata.org/entity/Q33398722

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Randomized phase II/III trial ...... hemotherapy: EORTC study 30986

@ast

Randomized phase II/III trial ...... hemotherapy: EORTC study 30986

@en

type

label

Randomized phase II/III trial ...... hemotherapy: EORTC study 30986

@ast

Randomized phase II/III trial ...... hemotherapy: EORTC study 30986

@en

prefLabel

Randomized phase II/III trial ...... hemotherapy: EORTC study 30986

@ast

Randomized phase II/III trial ...... hemotherapy: EORTC study 30986

@en

P1433

Q33398722-7C90C1A8-964A-4E56-82CD-5A2319352C25

P1476

Q33398722-F6BCF970-F946-48C5-A96D-2BD7976347F5

P2093

Q33398722-003F9EF0-AA89-4371-A989-BAAD47E594E5

Q33398722-111E7EB9-4A5B-4763-9733-B7CDFAFD9A3A

Q33398722-2DF41695-7D09-48B3-BA03-9CE53AD1D835

Q33398722-479871BA-55B3-46EA-98CD-520C13A2A737

Q33398722-6CC0E67A-B979-4A2F-BB48-C96F66D80E0C

Q33398722-789FF098-BDB4-433D-80F0-E4347B4C1A42

Q33398722-8406300A-333B-49FE-B72B-5F30067EE430

Q33398722-C81A5C54-EC92-4247-96F5-0C82B4E71C69

Q33398722-D412CE5D-F39E-4076-81E3-78ED577D743F

Q33398722-D9F9DA0D-FF11-4D2A-9775-D08D0B01B237

P2860

Q33398722-007F98D4-4B25-4A34-974B-9366B14E21FE

Q33398722-01450738-6230-4207-8B3F-84B566EDDCF7

Q33398722-10CB48BE-51A1-4394-A180-F9CD6F8E28AA

Q33398722-14207BB3-8E83-483C-B200-510C34041A55

Q33398722-20DA89F3-C877-4D64-B6EF-C575E4411124

Q33398722-21ABE26E-78B3-49B9-9B6F-8F0FD7D16DEA

Q33398722-2B6E964E-9DBD-4D0F-B96E-9B13D4713D0F

Q33398722-47D752E4-A561-4A77-910D-A4363F3DC8E2

Q33398722-484F69F7-14AE-4E57-82DA-EE5DEEB7C1EA

Q33398722-4C8022C1-3FD8-4B9B-BE73-FB1CC8E8F285

P304

Q33398722-DFBCD02B-CA7D-4474-AE39-4478CFC180B0

P31

Q33398722-F3F54302-FE35-46F1-9D73-03682283CC6E

P356

Q33398722-CAF12356-3922-45FB-98AC-E9805E80DA05

P407

Q33398722-5558BD55-EF65-4B90-A3A6-1F6D8D9199AB

P433

Q33398722-1619FA4A-C773-451B-8DDF-1D26A66E5E5B

P478

Q33398722-C18A95A7-96CA-4888-9173-16CB75285080

P50

Q33398722-0C3D1516-67E3-4BCE-9FDA-E8D150CF272F

Q33398722-3974C99F-03E6-42AC-AC32-392EC3B67B92

P577

Q33398722-3CAEE887-86DD-4102-B9F7-947C01AA9890

P5875

Q33398722-5101F14A-B682-4838-99A8-4CA39577521C

P698

Q33398722-17F72E24-028D-4527-8BAC-6425F0B5D599

P921

Q33398722-89426240-0E5F-4345-B346-4CF1F6859D36

Q33398722-F0C5FD01-905F-40C0-9BEB-8B011F4BAFCA

Q33398722-F69D25CE-A06A-42B9-A53E-F5396D4D2A9D

P932

Q33398722-36233FFB-D4DB-4E2E-856F-74B1A66FA56F

P356

JCO.2011.37.3571

P1433

Journal of Clinical Oncology

P1476

Randomized phase II/III trial ...... hemotherapy: EORTC study 30986

@en

P2093

Graham Mead

http://www.w3.org/2001/XMLSchema#string

Iwona Skoneczna

http://www.w3.org/2001/XMLSchema#string

J Martijn Kerst

http://www.w3.org/2001/XMLSchema#string

Joaquim Bellmunt

http://www.w3.org/2001/XMLSchema#string

Julie Lorent

http://www.w3.org/2001/XMLSchema#string

Maria De Santis

http://www.w3.org/2001/XMLSchema#string

Pablo Maroto

http://www.w3.org/2001/XMLSchema#string

Richard Sylvester

http://www.w3.org/2001/XMLSchema#string

Ronald de Wit

http://www.w3.org/2001/XMLSchema#string

Sandra Collette

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Prediction of creatinine clearance from serum creatinine

Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer.

Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities.

A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study.

Carboplatin and urothelial tumors.

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

P304

191-199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.37.3571

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Gedske Daugaard

P577

2011-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51872090

http://www.w3.org/2001/XMLSchema#string

P698

22162575

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

phase III clinical trial

P932

3255563

http://www.w3.org/2001/XMLSchema#string